Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of rMenB±OMV NZ Vaccine in Children
NCT01027351Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Primary completion
- Sep 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, sponsored by Novartis. Started Jan 2010; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01027351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027351.